Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingIn Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753399

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753399

Breast Recurrence Score Test

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Breast Recurrence Score Test Market to Reach US$414.1 Million by 2030

The global market for Breast Recurrence Score Test estimated at US$249.0 Million in the year 2024, is expected to reach US$414.1 Million by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Stage 1 Breast Cancer Indication, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$158.4 Million by the end of the analysis period. Growth in the Stage 2 Breast Cancer Indication segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 13.9% CAGR

The Breast Recurrence Score Test market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$91.5 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Breast Recurrence Score Test Market - Key Trends & Drivers Summarized

How Is Genomic Profiling Revolutionizing Breast Cancer Prognosis and Treatment Planning?

The Breast Recurrence Score Test, most commonly associated with genomic assays like Oncotype DX, has dramatically transformed how clinicians assess the risk of breast cancer recurrence and make critical decisions about adjuvant therapy. This test evaluates the expression of a specific panel of cancer-related genes-typically 21 genes-to produce a personalized recurrence score that estimates the likelihood of distant cancer recurrence within ten years of initial treatment. Unlike traditional prognostic tools that rely heavily on clinical and pathological features such as tumor size, lymph node involvement, and hormone receptor status, the Breast Recurrence Score Test provides a molecular-level insight into tumor biology. This enables oncologists to better stratify patients into low, intermediate, or high-risk categories, tailoring treatment plans accordingly. For example, patients with a low recurrence score can often forgo chemotherapy, thus avoiding its considerable side effects without compromising survival outcomes. This has marked a significant paradigm shift in breast cancer care, moving toward precision oncology that emphasizes individualized treatment over one-size-fits-all protocols. The growing body of clinical evidence from landmark trials such as TAILORx and RxPONDER has validated the clinical utility of the test, boosting physician and patient confidence in its results. As awareness of the test’s capabilities grows, it is increasingly being integrated into standard care protocols for early-stage, hormone receptor-positive, HER2-negative breast cancer. The result is not just improved clinical outcomes, but enhanced patient satisfaction and quality of life. The test also aligns with the shift toward value-based healthcare, by enabling more cost-effective treatment planning and reducing unnecessary therapeutic interventions.

What Role Are Clinical Guidelines and Reimbursement Policies Playing in Driving Adoption?

The increasing integration of the Breast Recurrence Score Test into clinical guidelines and insurance reimbursement frameworks has played a critical role in accelerating its global adoption. Esteemed bodies such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the St. Gallen International Expert Consensus have incorporated the test into their formal guidelines for managing hormone receptor-positive, HER2-negative breast cancer. These endorsements have lent strong clinical credibility to the test, encouraging oncologists across the globe to adopt it as a routine diagnostic tool. In tandem, many public and private insurers-particularly in the U.S., Canada, and parts of Europe-have approved reimbursement for the test, recognizing its long-term value in improving patient outcomes and minimizing overtreatment. Reimbursement policies have a direct influence on test utilization, especially in countries with centralized healthcare systems, where approved diagnostic tests are more likely to be widely adopted. Moreover, expanding insurance coverage has facilitated access to the test for underserved populations, making precision oncology more equitable. Policy decisions have also been guided by economic evaluations that show the test can significantly reduce the costs associated with unnecessary chemotherapy, hospital stays, and long-term management of treatment-related side effects. In emerging markets, the inclusion of such genomic assays in public health strategies is slower but steadily increasing, as local regulatory bodies assess clinical data and cost-effectiveness reports. Additionally, pharmaceutical companies and diagnostic firms are actively engaging with health ministries and payers to establish pathways for test adoption. The alignment of medical necessity, policy support, and cost-containment objectives has solidified the Breast Recurrence Score Test’s place in contemporary cancer care.

Are Technological Advancements Enhancing Test Accuracy and Global Accessibility?

The evolution of molecular diagnostics technology has greatly enhanced the accuracy, scalability, and accessibility of Breast Recurrence Score Tests. Originally processed only in centralized labs with long turnaround times, newer iterations benefit from streamlined sample processing, faster gene expression analysis, and increasingly robust algorithms that ensure precise recurrence risk calculation. The improvement in RNA extraction techniques and real-time PCR platforms has led to more reproducible results, even from small biopsy samples, thus making the test more versatile across clinical scenarios. Technological innovation has also expanded the range of usable specimen types, including core needle biopsies and formalin-fixed paraffin-embedded tissues, further simplifying the logistics of test administration. As genomic databases grow and machine learning becomes more integrated into oncology research, future enhancements in recurrence scoring may also incorporate additional data such as patient demographics, comorbidities, and immune profiles for even more individualized risk assessment. In terms of accessibility, partnerships between diagnostic developers and regional pathology labs are enabling decentralized testing models, allowing quicker turnaround times and lowering the barrier to adoption in lower-resource settings. Digital pathology and cloud-based data transfer systems also facilitate remote consultation and peer review, bridging the gap between urban and rural cancer centers. The miniaturization of lab instrumentation and the advent of automated genomic analysis are making it feasible for smaller healthcare facilities to offer these tests with high accuracy. Collectively, these innovations not only ensure consistent performance across patient populations but also play a crucial role in scaling up test availability globally-making personalized breast cancer care a tangible reality for more women, regardless of geographic location.

What Key Market Forces Are Driving the Expansion of Breast Recurrence Score Testing Worldwide?

The growth in the Breast Recurrence Score Test market is driven by several factors directly linked to changing cancer care protocols, technological maturity, and shifting patient expectations. A major driver is the global rise in breast cancer incidence, particularly among younger populations and in developing regions where awareness and early diagnosis are rapidly improving. This has created a strong demand for tools that can personalize treatment and avoid the physical, emotional, and financial toll of overtreatment. Concurrently, the shift toward de-escalation of therapy-especially chemotherapy-in early-stage breast cancer has positioned recurrence score tests as critical decision-making aids. Healthcare providers are increasingly seeking diagnostic tools that provide actionable insights, and the Breast Recurrence Score Test fits that role by delivering clinically validated, easy-to-interpret results that directly influence treatment pathways. Moreover, a growing population of well-informed patients is demanding transparency and precision in their care, leading oncologists to adopt genomic testing not just as a recommendation, but as a standard of care. On the provider side, multi-disciplinary tumor boards and value-based healthcare models are further promoting test usage to optimize resource utilization and outcomes. Another important market force is the active role of diagnostic companies in expanding their global footprint through strategic partnerships, awareness campaigns, and clinician education programs. These efforts are particularly impactful in Asia-Pacific and Latin American regions, where local validation studies and regulatory approvals are gaining momentum. Finally, the broader movement toward integrating genomics into routine oncology practice-from biomarker-based treatment to risk stratification-has created a fertile environment for the sustained growth of recurrence score testing. These interconnected factors-epidemiological, clinical, economic, and technological-are collectively ensuring that the global market for Breast Recurrence Score Tests remains on a robust upward trajectory.

SCOPE OF STUDY:

The report analyzes the Breast Recurrence Score Test market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication, Lymph-Node-Negative Cancer Indication); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Agendia
  • Biocartis
  • Bio-Rad Laboratories
  • Caris Life Sciences
  • Epic Sciences
  • Exact Sciences
  • Foundation Medicine
  • Guardant Health
  • Hologic Inc.
  • Illumina Inc.
  • Myriad Genetics
  • NanoString Technologies
  • Natera
  • OncoDNA
  • Oncomatryx
  • Qiagen
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Varian Medical Systems

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36424

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Breast Recurrence Score Test - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Precision Oncology Throws the Spotlight on Breast Recurrence Score Tests as Prognostic Tools
    • Shift Toward Personalized Breast Cancer Treatment Spurs Growth in Genomic Recurrence Risk Testing
    • Here's How Clinical Guidelines Are Driving Adoption of Recurrence Score Tests to Inform Chemotherapy Decisions
    • Expanding Use in Early-Stage HR-Positive, HER2-Negative Breast Cancer Strengthens the Business Case for Risk Stratification
    • Increased Physician and Patient Awareness Fuels Demand for Evidence-Based, Genomic-Driven Treatment Planning
    • Here's the Story: How TAILORx and RxPONDER Trial Results Are Validating Clinical Utility Across Demographics
    • Integration with Electronic Health Records and Oncology Decision Support Systems Enhances Workflow Efficiency
    • Growing Emphasis on Avoiding Overtreatment Supports the Economic Value Proposition of Recurrence Score Testing
    • Global Expansion of Molecular Pathology Labs Enables Broader Access in Developed and Emerging Markets
    • Rising Incidence of Breast Cancer Worldwide Expands the Addressable Market for Genomic Recurrence Assays
    • Innovation in Liquid Biopsy and Multi-Gene Panels May Disrupt or Complement Current Recurrence Score Test Models
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Recurrence Score Test Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Stage 1 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Stage 2 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lymph-Node-Negative Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!